- Article
- Source: Campus Sanofi
- Jul 17, 2026
Dupilumab Maintained Histologic and Endoscopic Improvements During the Open-Label Extension Period of the EoE KIDS Study
The Disease
- Eosinophilic esophagitis (EoE) is a long-term, inflammatory disease of the esophagus, affecting children and adults
- In children, it causes symptoms such as vomiting, pain, and difficulty maintaining a healthy weight, and significantly impacts quality of life
The Study
- Dupilumab is a biologic medication that blocks the pathways leading to inflammation in EoE
- The EoE KIDS study assessed whether dupilumab reduced markers of EoE in 102 affected children 1–11 years of age compared with a dummy treatment (placebo)
Treatments
- The EoE KIDS study looked at a higher dose or lower dose of dupilumab compared with placebo up to Week 16
- From Week 16 to Week 52, patients either continued the same dupilumab dose or switched from placebo to higher-dose or lower-dose dupilumab
- From Week 52 up to Week 100, eligible patients who continued from Part B into Part C, received an open-label dupilumab dose later approved by the FDA (similar to the higher dose used up to Week 52)
- Of the 37 patients who did not enter Part C from Part B, 18 were ineligible due to age
Chehade M, et al. Long-Term Dupilumab Maintains Histologic and Endoscopic Improvements in Children With Eosinophilic Esophagitis (EoE): 100-Week Results From the Open-Label Extension (OLE) of the EoE KIDS Study.Presented at the United European Gastroenterology Week (UEGW) 2025: Messe Berlin, Berlin, Germany; October 4–7, 2025.
EoE, eosinophilic esophagitis; EoEHSS, Eosinophilic Esophagitis Histologic Scoring System; EMA, European Medicines Agency; eos/hpf, eosinophils per high-power field; EREFS, Endoscopic Reference Score; FDA, US, Food and Drug Administration; HE, higher-exposure; hpf, high-power field; IL, interleukin; LE, lower-exposure; OLE, open-label extension; PEC, peak intraepithelial esophageal eosinophil count; PESQ-C, Pediatric EoE Sign/Symptom Questionnaire Caregiver version;PPI, proton-pump inhibitor; SD, standard deviation; STC, swallowed topical corticosteroid; TEAE, treatment-emergent adverse event; TE SEA, treatment-emergent serious adverse event; W, Week.
- Straumann A, Katzka DA. Gastroenterology. 2018;154:346–59.
- Mukkada V, et al. Clin Gastroenterol Hepatol. 2018;16:495–503.
- Stern E, et al. Dis Esophagus. 2018;31(4):1-7.
- Dellon ES, Hirano I. Gastroenterology. 2018;154(2):319-32.
- Straumann A, et al. Allergy. 2012;67:477-490.
- Barni S, et al. Ital J Pediatr. 2021;47:230.
- Chehade M, et al. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.e5.
- O’Shea KM, et al. Gastroenterology. 2018;154:333–45.
- Le Floc’h A, et al. Allergy. 2020;75:1188–204.
- Gandhi NA, et al. Expert Rev Clin Immunol. 2017;9:425–37.
- Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52.
- Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153.
- DUPIXENT® (dupilumab). Highlights of Prescribing Information. US Food and Drug Administration. Revised September 2024. Available from: https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed February 2025.
- DUPIXENT® (dupilumab). Summary of Product Characteristics. European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed February 2025.
- Chehade M, et al. N Engl J Med. 2024;390:2239–51.
Acknowledgments and funding sources: Data first presented at Digestive Disease Week 2025 (DDW): May 3–6, 2025; San Diego, CA, USA. Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov identifier: NCT04394351.
Medical writing/editorial assistance was provided by Emily Prior, MSc, of Adelphi Communications, Bollington, UK, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.
Disclosures: Chehade M: Adare Pharma Solutions/Ellodi, Allakos, AstraZeneca, BMS, Nexstone Immunology, Phathom, Recludix Pharma, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda – consultant; Adare Pharma Solutions/Ellodi, Allakos, AstraZeneca, Celgene/BMS, Danone, Regeneron Pharmaceuticals Inc., Shire/Takeda – research funding. Dellon ES: AbbVie, Adare/Ellodi, Akesobio, Alfasigma, ALK, Allakos, Amgen, Apollo, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biocryst, Bryn, Calypso, Celgene/Receptos/BMS, Celldex, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Sanofi, Shire/Takeda, Target RWE, Upstream Bio – consultant; Allakos, Aqilion, Holoclara, Invea – educational grant. Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celldex, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Sanofi, Shire/Takeda – research funding; Allakos, Aqilion, Holoclara, Invea – educational grant. Pesek RD: Regeneron Pharmaceuticals Inc. – advisory board. Collins MH: Alimentiv, Allakos, Arena, AstraZeneca, BMS, Calypso, EsoCap, GSK, Regeneron Pharmaceuticals Inc., Shire – consultant. Ashok D: Alexion Pharma, LaunchitDTx, Mirum Pharma – consulting fees. Sanofi – speaker fees. Liu R, Radin A: Regeneron Pharmaceuticals Inc. – employees and shareholders. Louisias M: Sanofi – employees, may hold stock and/or stock options in the company.
MAT-BH-2600389-V1-July2026